restricting the use of Trovan (trovafloxacin)

July 1999

Both the FDA and HPB are restricting the use of Trovan (trovafloxacin)...too many cases of severe liver toxicity.

Since Trovan came out last year, there have been over 100 reports of liver toxicity...including 6 deaths.

Now Trovan is recommended ONLY for patients with potentially life-threatening infections...who begin therapy in hospitals or long-term care facilities.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote